What Are SARS-CoV-2 Antivirals? Uses, Dosage, and What You Need to Know in 2026

SARS-CoV-2 is the virus that causes COVID-19. Since the pandemic began, researchers and pharmaceutical companies have developed several antiviral medications specifically designed to fight SARS-CoV-2 in the body. In 2026, these treatments can dramatically reduce the risk of hospitalization and death for high-risk patients — but only if started quickly after a positive test.

Here's a comprehensive guide to what SARS-CoV-2 antivirals are, how they're used, and what you need to know as a patient in 2026.

What Is SARS-CoV-2?

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a coronavirus that emerged in 2019 and causes the respiratory illness COVID-19. The virus spreads primarily through respiratory droplets and can cause illness ranging from mild cold-like symptoms to severe pneumonia, respiratory failure, and death. High-risk groups — including older adults, people with chronic health conditions, and immunocompromised individuals — face significantly higher risks of severe outcomes.

What Are SARS-CoV-2 Antivirals?

SARS-CoV-2 antivirals are medications that directly target and interfere with the virus's ability to replicate inside your body. They are distinct from COVID-19 vaccines (which prevent infection) and immune modulators (which reduce the immune system's overreaction to severe infection). Antivirals work best when started early — ideally within the first three days of symptom onset, and no later than five days.

FDA-Approved and Authorized COVID-19 Antivirals in 2026

As of 2026, these are the main antiviral options for outpatient COVID-19 treatment:

1. Paxlovid (Nirmatrelvir/Ritonavir)

• Manufacturer: Pfizer
• FDA status: Fully approved for adults 18+ (May 2023); EUA for adolescents 12–17 weighing at least 40 kg
• Indication: Mild-to-moderate COVID-19 in patients at high risk for progression to severe disease
• Dosage: Nirmatrelvir 300 mg + Ritonavir 100 mg, taken orally twice daily for 5 days (three tablets per dose, six per day). Renal dose pack (150/100 mg) for patients with moderate kidney impairment (eGFR 30–59 mL/min).
• Efficacy: Reduced risk of hospitalization or death by ~89% in unvaccinated high-risk patients in clinical trials (EPIC-HR)
• Key concern: Significant drug interactions due to ritonavir (CYP3A4 inhibitor). Always provide full medication list to prescriber.

38,004+ patients found their medications in stock

38K+

Find SARS-CoV-2 Treatment In Stock Today →

2. Remdesivir (Veklury)

• Manufacturer: Gilead Sciences
• FDA status: Fully approved for certain adults and children
• Outpatient dosage: 200 mg IV on Day 1, then 100 mg IV on Days 2 and 3. Administered at a clinic or infusion center.
• Best for: Patients who cannot take oral antivirals, have significant Paxlovid drug interactions, or need IV access.

3. Xocova (Ensitrelvir)

• Manufacturer: Shionogi
• FDA status: Approved June 2026 for post-exposure prophylaxis (prevention after close contact with an infected person)
• Key advantage: No ritonavir boosting required → significantly fewer drug interactions than Paxlovid

Skip the calls, skip the stress.

Find SARS-CoV-2 Treatment In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Who Qualifies for COVID-19 Antiviral Treatment?

COVID-19 antivirals are intended for patients at high risk of severe illness. High-risk factors include:

• Age 50 or older (especially 65+)
• Diabetes, obesity (BMI ≥30), heart disease, chronic lung disease, kidney disease
• Immunocompromised status (transplant, cancer treatment, HIV, autoimmune conditions)
• Not up to date on COVID-19 vaccination
• Depression or anxiety (recognized as risk factors by the CDC)

How to Get SARS-CoV-2 Antiviral Treatment

COVID-19 antivirals require a prescription. After testing positive:

1. Contact your doctor, urgent care, a telehealth platform, or a pharmacy clinic immediately
2. Provide your complete medication list for drug interaction screening
3. [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop
4. Enroll in PAXCESS assistance program if uninsured or on Medicare/Medicaid (paxlovid.com, 1-877-219-7225)

For help locating a pharmacy with COVID-19 antivirals in stock, visit medfinder.com.